Literature DB >> 11501988

Rationale for combination antifungal therapy.

R E Lewis1, D P Kontoyiannis.   

Abstract

The relentless increase of invasive fungal infections and poor outcomes associated with available antifungal agents prompted the search for better therapeutic strategies. Combining antifungal drugs was recommended as a means to enhance efficacy in a variety of invasive infections including cryptococcosis, candidiasis, and aspergillosis. With the exception of cryptococcal meningitis, data from controlled clinical trials supporting such combinations are sparse. Moreover, little consensus exists regarding which combinations are synergistic or antagonistic in vitro and in vivo. Based on available data, several principles underlie these combinations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11501988     DOI: 10.1592/phco.21.12.149s.34505

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  30 in total

Review 1.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

Authors:  Donna M MacCallum; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  Combination antifungal therapy for the treatment of invasive yeast and mold infections.

Authors:  John W Baddley; Peter G Pappas
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

5.  Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.

Authors:  Hua Quan; Ying-Ying Cao; Zheng Xu; Jing-Xia Zhao; Ping-Hui Gao; Xiao-Feng Qin; Yuan-Ying Jiang
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

6.  Use of Antifungal Combination Therapy: Agents, Order, and Timing.

Authors:  Melissa D Johnson; John R Perfect
Journal:  Curr Fungal Infect Rep       Date:  2010-05-01

Review 7.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

8.  Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  In vitro synergistic activity of diketopiperazines alone and in combination with amphotericin B or clotrimazole against Candida albicans.

Authors:  S Nishanth Kumar; Bala Nambisan; C Mohandas; A Sundaresan
Journal:  Folia Microbiol (Praha)       Date:  2013-02-28       Impact factor: 2.099

Review 10.  Invasive fungal infections: the challenge continues.

Authors:  Antonino Gullo
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.